ALXA - Alexza Pharmaceuticals, Inc.

Alexza Pharmaceuticals, Inc. was a biopharmaceutical company that focused on the research, development, and commercialization of novel, proprietary products for the acute treatment of central nervous system conditions. The company was founded in 2000 and based in Mountain View, California.

Alexza's lead product candidate was ADASUVE (loxapine) inhalation powder, which was developed for the rapid treatment of agitation in adults with schizophrenia or bipolar disorder. The company had also developed a number of other product candidates based on its proprietary Staccato system, which enabled the rapid delivery of drugs through the lungs.

In 2016, Alexza announced that it had entered into a merger agreement with an indirect wholly owned subsidiary of Grupo Ferrer Internacional, S.A., a privately held Spanish pharmaceutical company. Under the terms of the agreement, Ferrer acquired all outstanding shares of Alexza for $0.90 per share in cash, valuing the company at approximately $31.8 million. The merger was completed in March 2016 and Alexza became a wholly owned subsidiary of Ferrer. As of 2023, Alexza is no longer a publicly traded company.